Incyte Genomics Inc (INCY) Stock Price

INCYStock

$129.72+50.49%52W

Market Cap$26.29B

P/E18.97x

PEG Ratio30.83

Div yield—

Beta0.74

INCY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)13.02%

Price vs S&P 500 (4W)-4.55%

PEG Ratio30.83

VGM Score70.43

P/E Ratio (Annual)18.97x

P/CF (Annual)17.27x

Book Value / Share (Quarterly)$31.57

P/TBV (Annual)3.84x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.84%

Cash Flow / Share (Quarterly)$9.56

Price vs S&P 500 (YTD)17.61%

Gross Margin (TTM)93.09%

Net Profit Margin (TTM)27.71%

EPS (TTM)$7.85

10-Day Avg Trading Volume1.19M

EPS Excl Extra (TTM)$7.85

Revenue Growth (5Y)14.03%

EPS (Annual)$6.41

ROI (Annual)24.73%

Gross Margin (Annual)93.26%

Net Profit Margin (5Y Avg)16.76%

Cash / Share (Quarterly)$22.57

P/E Basic Excl Extra (TTM)15.14x

Revenue Growth QoQ (YoY)37.72%

P/E Normalized (Annual)18.97x

ROA (Last FY)18.49%

Revenue Growth TTM (YoY)26.93%

EBITD / Share (TTM)$8.80

ROE (5Y Avg)14.06%

Operating Margin (TTM)30.56%

Cash Flow / Share (Annual)$6.83

P/B Ratio3.85x

P/B Ratio (Quarterly)3.57x

Net Income / Employee (Annual)$452,400

EV / Revenue (TTM)3.52x

Net Interest Coverage (TTM)6.86x

ROA (TTM)22.63%

EPS Growth QoQ (YoY)38.02%

EV / EBITDA (TTM)11.33x

EPS Incl Extra (Annual)$6.41

Current Ratio (Annual)3.32x

Quick Ratio (Quarterly)4.31x

3-Month Avg Trading Volume1.73M

52-Week Price Return50.49%

EV / Free Cash Flow (Annual)15.10x

P/E Incl Extra (TTM)15.14x

Revenue / Employee (TTM)$2,046,200

Tangible BV / Share (Quarterly)$31.05

P/S Ratio (Annual)4.75x

Asset Turnover (Annual)0.74x

52-Week High$132.60

Operating Margin (5Y Avg)16.88%

EPS Excl Extra (Annual)$6.41

CapEx CAGR (5Y)-20.67%

Tangible BV CAGR (5Y)15.67%

26-Week Price Return24.26%

Quick Ratio (Annual)3.04x

13-Week Price Return31.38%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)4.59x

Enterprise Value$20.46B

Revenue / Share Growth (5Y)15.94%

Asset Turnover (TTM)0.82x

Book Value / Share Growth (5Y)16.96%

Revenue / Employee (Annual)$1,807,800

Inventory Turnover (Annual)4.33x

Pretax Margin (Annual)32.37%

Cash / Share (Annual)$18.04

3-Month Return Std Dev38.39%

Gross Margin (5Y Avg)94.07%

Net Income / Employee (TTM)$566,900

EBITDA Interim CAGR (5Y)36.97%

ROE (Last FY)24.90%

Net Interest Coverage (Annual)12.38x

EPS Basic Excl Extra (Annual)$6.41

P/FCF (TTM)12.71x

Receivables Turnover (TTM)5.91x

EV / Free Cash Flow (TTM)10.65x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$7.85

Receivables Turnover (Annual)5.48x

ROI (TTM)29.42%

P/S Ratio (TTM)4.19x

Pretax Margin (5Y Avg)19.42%

Revenue / Share (Annual)$25.62

Tangible BV / Share (Annual)$25.45

Forward P/E18.10x

Price vs S&P 500 (52W)32.18%

P/E Ratio (TTM)15.14x

EPS Growth TTM (YoY)80.31%

Year-to-Date Return29.57%

5-Day Price Return3.65%

EPS Normalized (Annual)$6.41

ROA (5Y Avg)10.59%

Net Profit Margin (Annual)25.03%

Month-to-Date Return7.08%

Cash Flow / Share (TTM)$2.23

EBITD / Share (Annual)$7.68

EPS Growth (3Y)61.53%

Operating Margin (Annual)29.46%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)12.33x

ROI (5Y Avg)13.96%

P/E Excl Extra (TTM)15.14x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$7.85

P/TBV (Quarterly)3.63x

P/B Ratio (Annual)3.75x

Inventory Turnover (TTM)4.10x

Pretax Margin (TTM)33.81%

Book Value / Share (Annual)$26.04

Price vs S&P 500 (13W)28.59%

Beta0.74x

P/FCF (Annual)18.02x

Revenue / Share (TTM)$27.95

ROE (TTM)29.60%

52-Week Low$81.09

vGradeC

gGradeA

mGradeB

vgmGradeB

INCY Earnings Surprise History

Q2 251.57est. 1.47

Q3 252.26est. 1.64

Q4 251.80est. 1.92

Q1 261.81est. 1.34

Q2 263.09est. 2.15

INCY Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.70

3.66

3.76

Industry Peers — R&D — Physical Sciences(16)

Symbol	Value Score	Growth Score	Momentum Score	Price
INCYIncyte Genomics Inc	C	A	B	$129.72
IQVIQVIA Holdings Inc.	D	C	A	$259.42
MEDPMedpace Holdings, Inc. Common Stock	F	B	A	$614.06
CRLCharles River Laboratories International, Inc.	D	D	A	$297.64
ICLRIcon Plc	C	C	B	$168.91
ABSIAbsci Corporation Common Stock	F	F	A	$9.63
OABIOmniAb, Inc. Common Stock	D	C	A	$4.66
NRCNRC Health Common Stock	D	D	B	$22.02
MXCTMaxCyte, Inc. Common Stock	C	D	B	$1.35
IBACIB Acquisition Corp. Common Stock	—	D	C	$10.89
ONMDOneMedNet Corp Class A Common Stock	D	C	D	$0.59
ISPCiSpecimen Inc. Common Stock	D	F	F	$1.60
BIAFbioAffinity Technologies, Inc. Common Stock	A	F	F	$5.19
BIAFWbioAffinity Technologies, Inc. Warrant	—	—	C	$0.08
NOTVInotiv, Inc. Common Stock	A	B	F	$0.01
OABIWOmniAb, Inc. Warrant	—	—	B	$0.23
ONMDWOneMedNet Corp Warrant	—	—	F	$0.03

About Incyte Genomics Inc

Incyte is a biopharmaceutical company specializing in small-molecule therapies for oncology, rheumatology, and dermatology. Jakafi, its flagship product for rare blood cancers and graft versus host disease, is co-developed with Novartis. The company markets multiple approved drugs including Olumiant (with Eli Lilly), Iclusig, Pemazyre, Tabrecta, Monjuvi, and the dermatology product Opzelura for atopic dermatitis and vitiligo. Its pipeline includes additional oncology and dermatology candidates.